Trial Profile
A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM).
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms MAPS
- 01 Jun 2022 Samples from this study used to assess the defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma published in the International Journal of Cancer
- 11 Feb 2019 Results evaluating their prognostic value for overall survival published in the British Journal of Cancer.
- 05 Jun 2018 Results assessing health-related quality of life, presented at the 54th Annual Meeting of the American Society of Clinical Oncology